Axsome Therapeutics, Inc. (AXSM) stock intrinsic value fair value estimate & owner earnings analysis

Axsome Therapeutics sells three approved brain-health medicines: AUVELITY (major depressive disorder, launched October 2022), SUNOSI (excessive daytime sleepiness in sleep apnea and narcolepsy) and SYMBRAVO (acute migraine, launched June 2025). Revenue has grown fast: $270.6 million in 2023 (including a one-time $65.7 million license payment), $385.7 million in 2024 and $638.5 million in 2025, then $409.6 million in the first half of 2026 versus $271.5 million a year earlier. Gross margins are very high (cost of revenue was about $47 million on 2025 revenue of $638 million). The catch is what it costs to sell and develop them: 2025 selling and administrative spending was $570.6 million (including $167.1 million of advertising, much of it a national consumer campaign for AUVELITY) and research spending was $183.3 million. Owner earnings, meaning operating cash flow after removing working-capital swings, stock-based pay and equipment spending, have been negative every year: about -$3.96 per share in 2023, -$5.16 in 2024 and -$3.30 in 2025 (roughly -$164 million in 2025 on 49.7 million diluted shares). Stock compensation of $93.8 million in 2025 is treated as a real cost. Early-2026 results do not yet show the losses closing: net loss was $115.9 million in the first half of 2026 versus $107.4 million in the first half of 2025, because costs grew about as fast as revenue. Operating cash outflow did improve, to $53.7 million from $75.8 million. Growth check: owner earnings per share improved from -$5.16 to -$3.30 in the last full year. We assume no further improvement in year one, which is below that trailing rate, because the latest half-year shows costs matching revenue growth and we can point to no dated reason for that to reverse. Bear case: $0 per share. Spending keeps pace with revenue, so the business keeps burning cash. The company borrowed under a Blackstone loan agreement in May 2025 ($120 million funded at closing, up to $570 million available, maturing May 8, 2030, with a $30 million minimum cash covenant), and the lenders rank ahead of shareholders. We find nothing we can name and evidence that turns the current cost structure into a profit, so this case is worth nothing to shareholders. Base case: $0 per share. Revenue holds at the current run rate (about $218 million in the second quarter of 2026) and costs stay where they are, so owner earnings remain negative. We do not credit further revenue growth or profit-margin improvement: growth from new prescriptions, share gains, the new SYMBRAVO launch and pipeline drugs has not yet turned into earnings, and management's stated goal of reaching positive cash flow is a target, not a result. The base case is not a claim that the business is worthless in every scenario; it is that nothing we can evidence today supports a positive value. Bull case: about $12 per share. Revenue keeps growing from about $860 million in 2026 to roughly $1.35 billion by 2030, and 60% of each additional revenue dollar reaches owner earnings (the 2025 actual was about 33%, and gross margin is about 93%). Owner earnings turn positive in 2028 and reach about $104 million a year from 2030. AUVELITY's patent settlement with Teva allows a generic to be sold from March 31, 2039 at the earliest (later if pediatric exclusivity applies), so we credit cash flow through 2038, half of 2039 and nothing after. SYMBRAVO patent claims extend to 2045, but we credit no value beyond 2039 because no earnings can yet be named. Discounted at 6%, this is worth roughly $12 per share. What would make this wrong: if selling costs, especially the consumer advertising campaign, are cut without slowing sales, the business could earn far more than we credit. Conversely, a generic or competitor entering before 2039, or further loan draws, would weaken it. Amounts owed to Blackstone are not deducted in the values above; leverage is reflected in the weak bear case. The margin-of-safety price is $2.00, reflecting a very wide margin of safety for an unprofitable, patent-dependent company, and it assumes three consecutive quarters of positive cash after stock compensation.